Multidrug-resistant tuberculosis in europe, 2010-2011

G. Günther; F. Van Leth; S. Alexandru; N. Altet; K. Avsar; D. Bang; R. Barbuta; G. Bothamley; A. Ciobanu; V. Crudu; M. Danilovits; M. Dedicoat; R. Duarte; G. Gualano; H. Kunst; W. De Lange; V. Leimane; C. Magis-Escurra; A.-M. McLaughlin; I. Muylle; V. Polcová; E. Pontali; C. Popa; R. Rumetshofer; A. Skrahina; V. Solodovnikova; V. Spinu; S. Tiberi; P. Viiklepp; C. Lange; M. Rowhani; V. Avchinko; D. Katovich; D. Klimuk; V. Lobik; Z. Rohaya; A. Shirochyn; J. Kotrbova; M. Vasakova; A.B. Andersen; N. Smitsman; R. Mütterlein; S. De Lorenzo; L. Rusmane; A. Donica; I. Cernenco; V. Dubceac; F. Cuppen; I. De Guchtenaire; R. Meesters; M. Te Pas; B. Prins; A. Atunes; D. Gainaru; E. Ibraim; M. Tigau; J. Cayla; L. Fina; M.L. De Souza Galvao; J. Maldonado

doi:10.3201/eid2103.141343

Multidrug-resistant tuberculosis in europe, 2010-2011

G. Günther
, F. Van Leth
, S. Alexandru
, N. Altet
, K. Avsar
, D. Bang
, R. Barbuta
, G. Bothamley
, A. Ciobanu
, V. Crudu
, M. Danilovits
, M. Dedicoat
, R. Duarte
, G. Gualano
, H. Kunst
, W. De Lange
, V. Leimane
, C. Magis-Escurra
, A.-M. McLaughlin
, I. Muylle

V. Polcová, E. Pontali, C. Popa, R. Rumetshofer, A. Skrahina, V. Solodovnikova, V. Spinu, S. Tiberi, P. Viiklepp, C. Lange, M. Rowhani, V. Avchinko, D. Katovich, D. Klimuk, V. Lobik, Z. Rohaya, A. Shirochyn, J. Kotrbova, M. Vasakova, A.B. Andersen, N. Smitsman, R. Mütterlein, S. De Lorenzo, L. Rusmane, A. Donica, I. Cernenco, V. Dubceac, F. Cuppen, I. De Guchtenaire, R. Meesters, M. Te Pas, B. Prins, A. Atunes, D. Gainaru, E. Ibraim, M. Tigau, J. Cayla, L. Fina, M.L. De Souza Galvao, J. Maldonado

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

© 2015, Centers for Disease Control and Prevention (CDC). All rights reserved.Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to >1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fuoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

Original language	English
Pages (from-to)	409-416
Journal	Emerging Infectious Diseases
Volume	21
Issue number	3
DOIs	https://doi.org/10.3201/eid2103.141343
Publication status	Published - 2015
Externally published	Yes

Access to Document

10.3201/eid2103.141343

Persistent URL (handle)

Persistent link

Cite this

Günther, G., Van Leth, F., Alexandru, S., Altet, N., Avsar, K., Bang, D., Barbuta, R., Bothamley, G., Ciobanu, A., Crudu, V., Danilovits, M., Dedicoat, M., Duarte, R., Gualano, G., Kunst, H., De Lange, W., Leimane, V., Magis-Escurra, C., McLaughlin, A.-M., ... Maldonado, J. (2015). Multidrug-resistant tuberculosis in europe, 2010-2011. Emerging Infectious Diseases, 21(3), 409-416. https://doi.org/10.3201/eid2103.141343

@article{dff2a1e085f94926b4be394185ea6850,

title = "Multidrug-resistant tuberculosis in europe, 2010-2011",

abstract = "{\textcopyright} 2015, Centers for Disease Control and Prevention (CDC). All rights reserved.Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4\% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7\% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1\% were resistant to >1 second-line drug, 26.6\% were resistant to second-line injectable drugs, 17.6\% were resistant to fuoroquinolones, and 6.8\% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.",

author = "G. G{\"u}nther and \{Van Leth\}, F. and S. Alexandru and N. Altet and K. Avsar and D. Bang and R. Barbuta and G. Bothamley and A. Ciobanu and V. Crudu and M. Danilovits and M. Dedicoat and R. Duarte and G. Gualano and H. Kunst and \{De Lange\}, W. and V. Leimane and C. Magis-Escurra and A.-M. McLaughlin and I. Muylle and V. Polcov{\'a} and E. Pontali and C. Popa and R. Rumetshofer and A. Skrahina and V. Solodovnikova and V. Spinu and S. Tiberi and P. Viiklepp and C. Lange and M. Rowhani and V. Avchinko and D. Katovich and D. Klimuk and V. Lobik and Z. Rohaya and A. Shirochyn and J. Kotrbova and M. Vasakova and A.B. Andersen and N. Smitsman and R. M{\"u}tterlein and \{De Lorenzo\}, S. and L. Rusmane and A. Donica and I. Cernenco and V. Dubceac and F. Cuppen and \{De Guchtenaire\}, I. and R. Meesters and \{Te Pas\}, M. and B. Prins and A. Atunes and D. Gainaru and E. Ibraim and M. Tigau and J. Cayla and L. Fina and \{De Souza Galvao\}, M.L. and J. Maldonado",

year = "2015",

doi = "10.3201/eid2103.141343",

language = "English",

volume = "21",

pages = "409--416",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "3",

}

Günther, G, Van Leth, F, Alexandru, S, Altet, N, Avsar, K, Bang, D, Barbuta, R, Bothamley, G, Ciobanu, A, Crudu, V, Danilovits, M, Dedicoat, M, Duarte, R, Gualano, G, Kunst, H, De Lange, W, Leimane, V, Magis-Escurra, C, McLaughlin, A-M, Muylle, I, Polcová, V, Pontali, E, Popa, C, Rumetshofer, R, Skrahina, A, Solodovnikova, V, Spinu, V, Tiberi, S, Viiklepp, P, Lange, C, Rowhani, M, Avchinko, V, Katovich, D, Klimuk, D, Lobik, V, Rohaya, Z, Shirochyn, A, Kotrbova, J, Vasakova, M, Andersen, AB, Smitsman, N, Mütterlein, R, De Lorenzo, S, Rusmane, L, Donica, A, Cernenco, I, Dubceac, V, Cuppen, F, De Guchtenaire, I, Meesters, R, Te Pas, M, Prins, B, Atunes, A, Gainaru, D, Ibraim, E, Tigau, M, Cayla, J, Fina, L, De Souza Galvao, ML & Maldonado, J 2015, 'Multidrug-resistant tuberculosis in europe, 2010-2011', Emerging Infectious Diseases, vol. 21, no. 3, pp. 409-416. https://doi.org/10.3201/eid2103.141343

TY - JOUR

T1 - Multidrug-resistant tuberculosis in europe, 2010-2011

AU - Günther, G.

AU - Van Leth, F.

AU - Alexandru, S.

AU - Altet, N.

AU - Avsar, K.

AU - Bang, D.

AU - Barbuta, R.

AU - Bothamley, G.

AU - Ciobanu, A.

AU - Crudu, V.

AU - Danilovits, M.

AU - Dedicoat, M.

AU - Duarte, R.

AU - Gualano, G.

AU - Kunst, H.

AU - De Lange, W.

AU - Leimane, V.

AU - Magis-Escurra, C.

AU - McLaughlin, A.-M.

AU - Muylle, I.

AU - Polcová, V.

AU - Pontali, E.

AU - Popa, C.

AU - Rumetshofer, R.

AU - Skrahina, A.

AU - Solodovnikova, V.

AU - Spinu, V.

AU - Tiberi, S.

AU - Viiklepp, P.

AU - Lange, C.

AU - Rowhani, M.

AU - Avchinko, V.

AU - Katovich, D.

AU - Klimuk, D.

AU - Lobik, V.

AU - Rohaya, Z.

AU - Shirochyn, A.

AU - Kotrbova, J.

AU - Vasakova, M.

AU - Andersen, A.B.

AU - Smitsman, N.

AU - Mütterlein, R.

AU - De Lorenzo, S.

AU - Rusmane, L.

AU - Donica, A.

AU - Cernenco, I.

AU - Dubceac, V.

AU - Cuppen, F.

AU - De Guchtenaire, I.

AU - Meesters, R.

AU - Te Pas, M.

AU - Prins, B.

AU - Atunes, A.

AU - Gainaru, D.

AU - Ibraim, E.

AU - Tigau, M.

AU - Cayla, J.

AU - Fina, L.

AU - De Souza Galvao, M.L.

AU - Maldonado, J.

PY - 2015

Y1 - 2015

N2 - © 2015, Centers for Disease Control and Prevention (CDC). All rights reserved.Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to >1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fuoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

AB - © 2015, Centers for Disease Control and Prevention (CDC). All rights reserved.Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to >1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fuoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

UR - https://www.scopus.com/pages/publications/84923127789

UR - https://www.scopus.com/pages/publications/84923127789#tab=citedBy

U2 - 10.3201/eid2103.141343

DO - 10.3201/eid2103.141343

M3 - Article

SN - 1080-6040

VL - 21

SP - 409

EP - 416

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

IS - 3

ER -

Multidrug-resistant tuberculosis in europe, 2010-2011

Abstract

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this